Acquired factor V deficiency (AFVD) is a rare but challenging
bleeding disorder with approximately 150 cases reported in the literature. Its
clinical presentation may span from the asymptomatic laboratory abnormalities to the life-threatening bleeding. Current recommendations emphasize the
importance of decreasing the anti-FV antibody titre only if bleeding symptoms
are present. (1) Based on this report, a new proposal for the treatment of
asymptomatic AFVD patients could be made
